These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34778803)

  • 1. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
    Richards RM; Zhao F; Freitas KA; Parker KR; Xu P; Fan A; Sotillo E; Daugaard M; Oo HZ; Liu J; Hong WJ; Sorensen PH; Chang HY; Satpathy AT; Majzner RG; Majeti R; Mackall CL
    Blood Cancer Discov; 2021 Nov; 2(6):648-665. PubMed ID: 34778803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative CAR targeting to selectively eliminate AML and minimize escape.
    Haubner S; Mansilla-Soto J; Nataraj S; Kogel F; Chang Q; de Stanchina E; Lopez M; Ng MR; Fraser K; Subklewe M; Park JH; Wang X; Rivière I; Sadelain M
    Cancer Cell; 2023 Nov; 41(11):1871-1891.e6. PubMed ID: 37802054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
    Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
    Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
    Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
    Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
    Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
    Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
    Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cells targeting FLT3 have potent activity against FLT3
    Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M
    Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
    Tashiro H; Sauer T; Shum T; Parikh K; Mamonkin M; Omer B; Rouce RH; Lulla P; Rooney CM; Gottschalk S; Brenner MK
    Mol Ther; 2017 Sep; 25(9):2202-2213. PubMed ID: 28676343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
    Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
    Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
    Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
    Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
    Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
    Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.
    John S; Chen H; Deng M; Gui X; Wu G; Chen W; Li Z; Zhang N; An Z; Zhang CC
    Mol Ther; 2018 Oct; 26(10):2487-2495. PubMed ID: 30131301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.